322 related articles for article (PubMed ID: 31692137)
1. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
Papaefthymiou A; Liatsos C; Georgopoulos SD; Apostolopoulos P; Doulberis M; Kyriakos N; Giakoumis M; Papadomichelakis M; Galanopoulos M; Katsinelos P; Rokkas T; Kountouras J
Helicobacter; 2020 Feb; 25(1):e12666. PubMed ID: 31692137
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
[TBL] [Abstract][Full Text] [Related]
3. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Sancar M; Izzettin FV; Apikoglu-Rabus S; Besisik F; Tozun N; Dulger G
Pharm World Sci; 2006 Aug; 28(4):207-14. PubMed ID: 17066247
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
7. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece.
Georgopoulos S; Papastergiou V; Xirouchakis E; Laudi F; Papantoniou N; Lisgos P; Spiliadi C; Fragou P; Skorda L; Karatapanis S
Helicobacter; 2012 Feb; 17(1):49-53. PubMed ID: 22221616
[TBL] [Abstract][Full Text] [Related]
10. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study.
Yi DM; Yang TT; Chao SH; Li YX; Zhou YL; Zhang HH; Lan L; Zhang YW; Wang XM; Zhang YR; Li J; Ding SZ
Medicine (Baltimore); 2019 Feb; 98(6):e14408. PubMed ID: 30732192
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.
Romano M; Marmo R; Cuomo A; De Simone T; Mucherino C; Iovene MR; Montella F; Tufano MA; Del Vecchio Blanco C; Nardone G
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):273-8. PubMed ID: 15017668
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
[TBL] [Abstract][Full Text] [Related]
14. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.
Tsay FW; Wu DC; Kao SS; Tsai TJ; Lai KH; Cheng JS; Chan HH; Wang HM; Tsai WL; Tseng HH; Peng NJ; Hsu PI
Helicobacter; 2015 Feb; 20(1):71-7. PubMed ID: 25495272
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against
Liatsos C; Papaefthymiou A; Kyriakos N; Giakoumis M; Kountouras J; Galanopoulos M; Apostolopoulos P; Georgopoulos SD; Mavrogiannis C; Exadaktylos AK; Srivastava DS; Rokkas T; Doulberis M
Medicina (Kaunas); 2020 Mar; 56(3):. PubMed ID: 32197498
[No Abstract] [Full Text] [Related]
16. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen.
Catalano F; Branciforte G; Catanzaro R; Cipolla R; Bentivegna C; Brogna A
Aliment Pharmacol Ther; 2000 Oct; 14(10):1329-34. PubMed ID: 11012478
[TBL] [Abstract][Full Text] [Related]
18. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
